MSD

Corporate brand

Unclaimed Request correction

MSD is a biopharmaceutical company in Athens, Greece, focused on research-driven medicines and vaccines.

Last updated September 10, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

MSD is a biopharmaceutical company in Athens, Greece. It describes itself as aspiring to be a research-focused biopharmaceutical company with a leading global position, developing innovative solutions for the prevention and treatment of diseases in humans and animals. In Greece, MSD focuses on areas such as oncology, vaccines, hospital care, pulmonary hypertension, and antimicrobial resistance.

History

MSD states that for more than 130 years it has contributed to health through the development of important medicines and vaccines. In Greece, MSD focuses on areas such as oncology, vaccines, hospital care, pulmonary hypertension, and addressing antimicrobial resistance, and it operates in Greece with a stable presence and an active role in supporting health innovation.

Products and positioning

Research-focused biopharmaceutical company with a leading global position, developing innovative solutions for prevention and treatment of diseases in humans and animals.

Oncology
Keytruda (Pembrolizumab)
Oncology
Lynparza (Olaparib)
Oncology
IVEMEND (Fosaprepitant dimeglumine)
Oncology
EMEND (Aprepitant)
Oncology
Temodal (Temozolomide)
Oncology
OncoTICE (Bacillus Calmette-Guerinn (BCG, strain tice))
Oncology
Welireg (Belzutifan)
Vaccines
MMR vaxPro
Vaccines
HBvaxPRO
Vaccines
VAQTA 25U
Vaccines
VAQTA 50U
Vaccines
VARIVAX
Vaccines
RotaTeq
Vaccines
ProQuad
Vaccines
Gardasil 9
Vaccines
Vaxelis
Vaccines
Vaxneuvance
Vaccines
Capvaxive
Endocrinology
Januvia (sitagliptin)
Endocrinology
Janumet (sitagliptin, metformin)
Infectious Diseases
Noxafil (Posaconazole)
Infectious Diseases
Isentress (Raltegravir)
Infectious Diseases
Zerbaxa (ceftolozane, tazobactam)
Infectious Diseases
Cubicin (Daptomycin)

Recent events

2026-08-19
MSD appoints Mary Srethapakdi as Managing Director for the Philippines[6]MSD任命Mary Srethapakdi为菲律宾董事总经理manilatimes.net
Reported: 2026-08-19
MSD in the Philippines, a trade name of Merck & Co., Inc, announced the appointment of Mary Srethapakdi as managing director for the Philippines, while she concurrently leads MSD's operations in Thailand. She succeeds Andreas Riedel, who has been appointed Managing Director for MSD Vietnam.
Unconfirmed
NOXXON and MSD collaborate on NOX-A12 study[7]NOXXON与MSD合作开展NOX-A12研究finanznachrichten.de
Reported: 2021-10-22
NOXXON and MSD entered a collaboration for MSD to provide pembrolizumab (Keytruda) and expert advice for the OPTIMUS study of NOX-A12 in second-line pancreatic cancer.
Unconfirmed
WEHI and MSD establish researcher exchange collaboration[8]WEHI 与 MSD 建立研究人员交流合作miragenews.com
WEHI and MSD established a three-year exchange program under which WEHI researchers can be seconded to MSD’s Research Laboratories; the agreement also gives MSD an exclusive option to license WEHI intellectual property.
2021-08-12
FDA approves Keytruda and Lenvima combination for advanced kidney cancer[9]FDA 批准 Keytruda 与 Lenvima 联合治疗晚期肾癌pharmatimes.com
Reported: 2021-08-12
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
2021-08-06
BioInvent and MSD enter a clinical-trial collaboration for BI-1808 and KEYTRUDA[10]BioInvent与MSD达成BI-1808和KEYTRUDA临床试验合作prnewswire.com
Reported: 2021-08-06
BioInvent announced a second clinical-trial collaboration and supply agreement with MSD to evaluate BioInvent’s BI-1808 with MSD’s KEYTRUDA in a Phase 1/2a trial involving patients with lung and ovarian cancer.
2021-04-07
Alkermes and MSD enter clinical trial collaboration[11]Alkermes与MSD达成临床试验合作prnewswire.com
Reported: 2021-04-07
Alkermes announced a clinical trial collaboration and supply agreement with MSD for a planned phase 3 study evaluating nemvaleukin alfa in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer. Alkermes is responsible for conducting the study, which was planned to initiate in the second half of 2021.
2021-04
FDA approves Novocure application to initiate KEYNOTE-B36 trial[12]FDA批准Novocure启动KEYNOTE-B36试验的申请finanznachrichten.de
Reported: 2021-04-29
Novocure reported that the U.S. FDA approved its investigational device exemption application to initiate the KEYNOTE-B36 phase 2 pilot trial studying TTFields with pembrolizumab in first-line non-small cell lung cancer.
2020-10-29
Sanofi and MSD agree to test THOR-707 with Keytruda[13]赛诺菲与MSD同意测试THOR-707与Keytruda的联合疗法pharmatimes.com
Reported: 2020-10-29
Sanofi entered an agreement with MSD to collaborate on a phase II trial evaluating Sanofi's investigational candidate THOR-707 alongside MSD's Keytruda.
2020-08-12
QBiotics and MSD clinical collaboration[14]QBiotics与MSD开展临床合作prnewswire.com
Reported: 2020-08-13
QBiotics announced that it had entered into an agreement with MSD to evaluate tigilanol tiglate in combination with Keytruda in patients with unresectable melanoma.
2020-08-07
MSD announces plan to acquire Takeda’s Dunboyne facility[15]MSD宣布计划收购Takeda的Dunboyne工厂siliconrepublic.com
Reported: 2020-08-10
MSD announced plans to acquire Takeda’s biologics manufacturing plant in Dunboyne, Ireland. The companies expected the staff consultation and transfer process to be completed in mid-September; the acquisition was not reported as completed.

Showing the 10 most recent.

Sources18 sources

Cite this profile: Cite the canonical profile. /brand-wiki/msd · Editorial policy · How profiles are compiled